Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Relapsed/Refractory Non-Hodgkin's Lymphoma Non-Hodgkin's lymphoma (NHL) confirmed by histopathology, preferably in the detection of tumor tissue PD-L1 expression. 2. A recurrent or refractory disease defined as: 1) recurrence of disease after complete remission (CR); or 2) partial remission (PR), disease stabilization (SD), or disease Progress (PD) when the treatment is completed prior to enrollment in the study. 3. Age≥18 years old, both men and women. 4. The ECOG score is 0-2. 5. There is at least one evaluable lesion (maximum diameter>15mm or shortest diameter>10mm). Preferably, PET-CT shows high metabolism of FDG. 6. Have received appropriate first-line and more-line treatment of the corresponding NHL. 7. Liver and kidney function: blood bilirubin≤35μmol/L, AST or ALT is less than 2 times the upper limit of normal value, serum creatinine≤150μmol/L. 8. The thyroid function is normal. 9. Women of childbearing age are required to undergo a pregnancy test before receiving treatment and must agree to take effective contraception during treatment. 10. Subjects must sign an informed consent form  Age<18 years old； 2. Received ASCT within 90 days prior to the first use of the study drug; 3. Severe allergies, or patients known to be allergic or intolerant of the drug components of the chemotherapy regimen; 4. Active, unrecognized or suspected autoimmune disease, or a history of autoimmune disease within 2 years; 5. Previously exposed to any antibody against PD-1, PD-L1 or cytotoxic T lymphocyte-associated antigen 4 6. Exposure to any study drug within 4 weeks prior to the first use of the study drug 7. Expose to the last radiotherapy or anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy or arterial embolization) within 3 weeks prior to the first use of the study drug. 8. Have a history of oncology and have received any treatment for this tumor in the past 3 years; 9. Patients during pregnancy and lactation; 10. Accompanied by severe heart disease, including acute myocardial infarction within 6 months, or in accordance with New York Heart Association cardiac function III or IV; 11. A serological test for HIV or active hepatitis C virus is known to be positive; 12. Hepatitis B virus carriers or hepatitis B virus DNA positive untreated patients are known; 13. TB patients active period 14. Other circumstances that the investigator believes are not suitable for inclusion